5-Amino-1MQ
MetabolicAlso known as 5-Amino-1-methylquinolinium
Evidence tier
Limited published literature
8 publications over 8 years · trials not yet curated
- Researched since
- 2018
- Publications
- 8
- Mean purity
- 99.7%
- Vendors listing
- 17
Next Gen Peptides shows the highest mean assayed purity for 5-Amino-1MQ at 100.0% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2018 — 8 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
8 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 19 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.23 pts purity across lots, mean label deviation 11.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
17 of 17 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
19 of 19 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is 5-Amino-1MQ?
A small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied in the context of metabolism and adipose tissue. It is supplied as a research chemical rather than a peptide.
Studied in published research for metabolic health and fat loss, as an inhibitor of the NNMT enzyme.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is preclinical, in cell and animal models of metabolism and obesity. PepIndex does not evaluate clinical significance and does not describe administration.
- NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer — Journal for immunotherapy of cancer (2024)
Peer-reviewed article indexed in PubMed, published in Journal for immunotherapy of cancer (2024).
- Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine — Atherosclerosis (2009)
Peer-reviewed article indexed in PubMed, published in Atherosclerosis (2009).
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice — Scientific reports (2022)
Peer-reviewed article indexed in PubMed, published in Scientific reports (2022).
- Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells — Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2021)
Peer-reviewed article indexed in PubMed, published in Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2021).
- Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes — Life sciences (2020)
Peer-reviewed article indexed in PubMed, published in Life sciences (2020).
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — Biochemical pharmacology (2018)
Peer-reviewed article indexed in PubMed, published in Biochemical pharmacology (2018).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 93.897% | — | 1 | 100.0% | 6.5% | |
| American PeptidesISO/IEC 17025 | 93.5100% | $1.60 (31%) | 0 | — | — | |
| Protide Health | 90.994% | $2.20 (42%) | 1 | 99.7% | 12.1% | |
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 2 | 99.7% | 8.8% | |
| PeptidePlugs | 89.790% | — | 6 | 99.8% | 11.0% | |
| Northline LabsISO/IEC 17025 | 79.493% | — | 1 | 100.0% | 7.4% | |
| ZC Labs | 79.384% | — | 2 | 99.7% | 14.5% | |
| Ascension Peptides | 78.186% | $5.20 (100%) | 1 | 99.5% | 27.9% | |
| Improved Peptides | 7789% | $1.30 (30%) | 0 | — | — | |
| NeuroLabs Research | 75.186% | $5.99 (115%) | 0 | — | — | |
| Modern AminosISO/IEC 17025 | 74100% | — | 4 | 99.5% | 8.7% | |
| BioLongevity Labs | 7374% | $5.00 (96%) | 0 | — | — | |
| Eternal Peptides | 70.665% | $4.00 (77%) | 0 | — | — | |
| Good Science Bio | 67.275% | $6.50 (125%) | 0 | — | — | |
| True Research Labs | 65.771% | $5.90 (114%) | 0 | — | — | |
| Licensed Peptides | 63.489% | $8.79 (169%) | 1 | 99.8% | 7.8% | |
| Mile High Compounds | 51.194% | $11.00 (212%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Ascend Science | AS-5AM5-2 | Kovera Labs | 5 mg | 5.1 mg | 2.0% | 99.6% | Vendor-published | |
| Ascend Science | AS-5AM50-2 | Kovera Labs | 50 mg | 57.77 mg | 15.5% | 99.8% | Vendor-published | |
| ZC Labs | ZCLa2607301119 | Freedom Diagnostics Testing | 50 mg | 55.35 mg | 10.7% | 99.7% | Vendor-published | |
| Protide Health | PH-51q50-0327 | Analysis FreedomDiagnostics | 50 mg | 56.05 mg | 12.1% | 99.7% | Vendor-published | |
| PeptidePlugs | 160-810L-DK | Freedom Diagnostics Testing | 10 mg | 10.63 mg | 6.3% | 99.8% | Vendor-published | |
| PeptidePlugs | 160-850L-DK | Freedom Diagnostics Testing | 50 mg | 50.57 mg | 1.1% | 99.5% | Vendor-published | |
| PeptidePlugs | 101-03-ZB | Freedom Diagnostics Testing | 10 mg | 11.04 mg | 10.4% | 99.8% | Vendor-published | |
| PeptidePlugs | 101-04-ZB | Freedom Diagnostics Testing | 50 mg | 57.72 mg | 15.4% | 99.9% | Vendor-published | |
| ZC Labs | ZCLa2607100472 | Freedom Diagnostics Testing | 10 mg | 8.18 mg | 18.2% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-E6Y2 | Analysis FreedomDiagnostics | 50 mg | 56.11 mg | 12.2% | 99.9% | Vendor-published | |
| Northline Labs | NLL-9485675 | ILS Laboratories | 5 mg | 5.37 mg | 7.4% | 100.0% | Vendor-published | |
| Next Gen Peptides | 5AM-CAP-02 | ILS Laboratories | 50 mg | 53.23 mg | 6.5% | 100.0% | Vendor-published | |
| PeptidePlugs | 124-02-SM | Freedom Diagnostics Testing | 50 mg | 58.52 mg | 17.0% | 99.7% | Vendor-published | |
| PeptidePlugs | 112-U-A | Freedom Diagnostics Testing | 10 mg | 11.54 mg | 15.4% | 99.8% | Vendor-published | |
| Licensed Peptides | 5AMINO-01 | Vanguard Laboratory | 5 mg | 5.39 mg | 7.8% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-G1N7 | Freedom Diagnostics Testing | 10 mg | 10.86 mg | 8.6% | 99.3% | Vendor-published | |
| Ascension Peptides | 36-01260229 | MZ Biolabs | 10 mg | 12.79 mg | 27.9% | 99.5% | Vendor-published | |
| Modern Aminos | BX-P-W9K2 | Freedom Diagnostics Testing | 10 mg | 9.55 mg | 4.5% | 99.6% | Vendor-published | |
| Modern Aminos | BX-C-Q7G2 | Vanguard Laboratory | 50 mg | 54.83 mg | 9.7% | 99.1% | Vendor-published |